tbuckley/cabot-search huggingface dataset:
TCT-716 A DW-MRI and MSCT-Study to assess predictors of cerebral embolism during transcatheter aortic valve implantation
Authors: Ermela Yzeiraj, Klaudija Bijuklic, Timo Haselbach, Korff Krause, Julian Witt, Lorenz Hansen, Friedrich-Christian Riess, Joachim Schofer
Journal: Journal of the American College of Cardiology (2016)
TCT-711 Clinical Relevance of Baseline and Post-procedural Thrombocytopenia in Patients Undergoing Transcatheter Aortic Valve Replacement: Prognostic Implications
Authors: Anna Sannino, ROBERT C. STOLER, ROBERT HEBELER, Molly Szerlip, Michael Mack, Paul Grayburn
Journal: Journal of the American College of Cardiology (2016)
TCT-739 Twelve-month follow-up results of the STASIS trial: a multi-center study on a novel apical closure device for transapical transcatheter aortic valve implantation
Authors: Hendrik Treede, Lenard Conradi, Thomas Walther, Joerg Kempfert, Sabine Bleiziffer, Walter Eichinger, Oliver Heyn, Hermann Reichenspurner, Riccardo Cocchieri, Ruediger Lange
Journal: Journal of the American College of Cardiology (2016)
TCT-178 Feasibility and safety of the “the one small catheter only” (TOSCO) strategy in patients with ST elevation myocardial infarction
Authors: Gregory Sgueglia, Gaetano Gioffrè, Antonella De Santis, Fabrizio D'Errico, Francesco Summaria, Achille Gaspardone
Journal: Journal of the American College of Cardiology (2016)
Endoscopic resection of sporadic duodenal neuroendocrine tumors: Why is this not so easy?
Authors: Pete Basford, Pradeep Bhandari
Journal: Endoscopy (2016)

Although duodenal neuroendocrine tumors (NETs) comprise only 2 % – 3 % of all NETs, their incidence appears to be rising, possibly as a result of the increasing use of upper gastrointestinal (GI) endoscopy [1] [2] [3]. The majority of these lesions are small and probably unrelated to the patient's symptoms, but once discovered, they pose a dilemma: removal of duodenal NETs is desirable because of the risk of developing lymph node or liver metastases, but performing endoscopic resection in the duodenum is by no means straightforward. This is a challenging portion of the GI tract for endoscopists, with high risks owing to the thin and richly vascular duodenal wall and access that is often difficult. This is reflected in the considerable complication rates associated with endoscopic resection of any lesions in the duodenum [4].
Developmental profile of ocular refraction in patients with congenital cataract: a prospective cohort study
Authors: Zhenzhen Liu, Erping Long, Jingjing Chen, Zhuoling Lin, Duoru Lin, Xiaohang Wu, Qianzhong Cao, Xiaoyan Li, Dongni Wang, Lixia Luo, Bo Qu, Runzhong Liu, Xiaopin Liu, Haotian Lin, Weirong Chen, Yizhi Liu
Journal: The Lancet (2016)
Correlation between hemodynamic parameters and response to high-dose interleukin-2 in metastatic melanoma
Authors: J. P. Dutcher, C. Dasanu, I. Codreanu, M. Yeddu, H. Muniswamy, P. H. Wiernik, D. T. Alexandrescu
Journal: Journal of Clinical Oncology (2006)

18012 Background: A direct correlation between the levels of hypotension during IL-2 treatment and response in melanoma has not yet been demonstrated, although both have been correlated with higher IL-2 doses and production of nitric oxide. Methods: A retrospective study analyzed the association between response to IL-2 and systolic, diastolic, mean blood pressure (BP), and heart rate (HR) at baseline and during treatment, by using the t-test. Further, same comparison was performed after BP was corrected for the amount of neosynephrine (neo) utilized during IL-2 treatment (subtracting the raise in BP produced by neo using individual patient coefficients). 22 patients (13 females, 9 males) with a median age of 54 years (range 36–71) received a total of 26 courses of IL-2 (between 2001–2005). Median number of prior treatments was 2.5 (range 0–5). Outcomes were divided in (A) responders (1CR, 3PRs and 4SDs), and (B) non-responders (18PD). Results: When adjusting for the effects of neo, the corrected mean BP during treatment was significantly lower in (A) compared to (B) (52.17 vs 64.34 mmHg, P = 0.018; mean difference −12.17, 95% CI −22.06 to −2.27). Similarly, the decrease in corrected mean blood pressure from baseline was greater in (A) (−34.89 vs −20.67 mmHg, P = 0.003; mean difference −14.22, 95% CI −23.09 to −5.37). A trend towards statistical significance was recorded for the variation in uncorrected mean BP (17.86 vs. 23.22 mmHg, P = 0.085; mean difference −5.36, 95% CI −11.53 to 0.80). Separate analysis demonstrated a significant drop in both systolic (−17.85 mmHg, P = 0.009; 95% −30.77 to −4.91) and diastolic (−12.05 mmHg, P = 0.01; 95% CI −21.02 to −3.07) corrected BP in (A) vs. (B), but no significant difference for either uncorrected parameters. No correlation between response and the HR, number of IL-2 doses or total quantity of neo was observed. Conclusions: Uncorrected variation in mean BP shows a trend towards significance in predicting response to IL-2. However, corrected mean, systolic and diastolic BP correlate closely with response to treatment. Implications of this association may reside in better outcomes for an intensive IL-2 treatment, with aggressive pressor support. A common pathogenetic basis for response to IL-2 and induction of hypotension is possible. No significant financial relationships to disclose.
Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems
Authors: Mohamed Abdelgadir Adam, Samantha Thomas, Terry Hyslop, Randall P. Scheri, Sanziana A. Roman, Julie A. Sosa
Journal: Journal of Clinical Oncology (2016)

Purpose Patient age is considered to play a unique prognostic role in papillary thyroid cancer (PTC), with a distinct staging dichotomization at 45 years of age. This is based on older, limited data demonstrating a marked rise in mortality around the ages of 40 to 50 years. We hypothesized that age is associated with compromised survival from cancer, with no cutoff denoting survival difference. Patients and Methods Patients with PTC who had surgery were identified from the SEER database (1998 to 2012). Multivariable proportional hazards modeling utilizing several flexible smoothing approaches were used to examine the association between age and cancer-specific survival (CSS) and to determine whether there is an age cut point that is associated with CSS decrement. Results A total of 31,802 patients with PTC were included. Median age was 45 years (range, 2 to 105 years). Ten-year CSS according to age was as follows: 2 to 19 years, 99.8%; 20 to 29 years, 99.9%; 30 to 39 years, 99.8%; 40 to 49 years, 99.5%; 50 to 59 years, 98.1%; 60 to 69 years, 94.8%; 70 to 79 years, 91.5%; 80 to 89 years, 79.2%; and ≥ 90 years, 73.9%. After adjustment for patient demographic and clinicopathologic characteristics, increasing age was associated with increasing mortality from the disease in a dose-dependent fashion, without an apparent cut point. Each of the smoothing approaches demonstrated a similar linearity of risk over all ages and provided close measures of goodness of fit to the data. Conclusion Patient age is significantly associated with death from PTC in a linear fashion, without an apparent age cut point demarcating survival difference. These results challenge the appropriateness of a patient age cut point in current staging systems for PTC and argue for considering a revision in how we anticipate prognosis for patients with PTC.
Loss-of-function genetic tools for animal models: cross-species and cross-platform differences
Authors: Benjamin E. Housden, Matthias Muhar, Matthew Gemberling, Charles A. Gersbach, Didier Y. R. Stainier, Geraldine Seydoux, Stephanie E. Mohr, Johannes Zuber, Norbert Perrimon
Journal: Nature Reviews Genetics (2016)
Liposomal doxorubicin (M) plus gemcitabine (G) as first line treatment in metastatic breast carcinoma: A phase I-II study
Authors: R. Colomer, I. Tusquets, L. Calvo, J. Dorca, E. Adrover, P. Sanchez-Rovira, J. Rifa, J. De La Haba, J. A. Virizuela, M. Beltran
Journal: Journal of Clinical Oncology (2006)

10651 Background: We designed a phase I-II trial to determine the combination dose of liposomal doxorubicin (Myocet) plus gemcitabine (Gemzar), and to evaluate the safety and feasibility of the regimen Methods: Patients with histologically confirmed breast cancer, untreated distant metastasis, age &gt;18 years old, left ventricular ejection fraction (LVEF) &gt;50% and adequate bone marrow, renal and hepatic function were included in the study. Patients received up to six cycles of treatment. No G-CSF support was used prophylactically. LVEF was repeated at 3, and 6 months, and every 6 months thereafter. Results: Phase I: After 6 patients, the recommended dose was M (55 mg/m 2 ) D1 and G (900 mg/m 2 ) D1 and 8, administered every 21 days. Phase II: 53 patients have been enrolled; 52 are included in the safety analysis and 42 in the efficacy analysis. The median age of the population was 61 years of age (32–79). ECOG PS was 0 in 55%, 1 in 41%, 2 in 4%. Postmenopausal status in 87%. Main histology was ductal carcinoma (85%). Prior adjuvant anthracyclines had been administered in 19 cases (median dose of doxorubicin: 300 mg/m 2 , or epirubicin: 425 mg/m 2 ). Metastasic lesions were in liver (25), lung (17), bone (16), and lymph nodes (25). Patients received a median number of 5 cycles (range 1–6). Median relative dose intensity was 83% for M and 75% for G. Grade III-IV hematologic toxicity per administered cycles was: leukopenia (21.9%), neutropenia (31.2%), febrile neutropenia (4 %), and thrombocytopenia (7.4%). Grade III-IV non-hematologic toxicities were stomatitis (4.8%), nausea (1.7%), vomiting (2.2%), asthenia (2.6%) and diarrhea (0.8%). Thirteen of 52 pts (25%) had alopecia grade III-IV. No signs or symptoms of cardiac impairment have been seen. An objective response rate of 62% was obtained (95% CI: 45.6- 76.4%). Two patients had complete response (4.8%), 24 partial response (57.1%), 10 stable disease and 6 progressive disease. The response rate was similar in patients with or without previous adjuvant anthracyclines (68.5% and 61%, respectively). Conclusions: The combination of liposomal doxorubicin plus gemcitabine has high efficacy and low toxicity in advanced breast cancer patients, and may be a valuable option in patients that have received adjuvant anthracyclines. [Table: see text]
TCT-172 The Effect of Obstructive Sleep Apnea on Outcomes in Patients with STEMI: An Age Stratified Analysis of Nationally Representative Data
Authors: Divyanshu Mohananey, Nirmanmoh Bhatia, None sahil agrawal, Jaskaran Sethi, Aswathi Chandaran, Ashish Aangl, Thelma Dangana, Zeeshan Hussain, Muhammad Ali, Pedro Villablanca
Journal: Journal of the American College of Cardiology (2016)
Pioneering Geneticist Explains Ambitious Plan to “Write” the Human Genome
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-105 Prevalence of prasugrel use and associations between type of acute coronary syndrome and 1-year clinical outcomes
Authors: Asim Rafique, Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa Aquino, Samir Kapadia, Sunil Rao, J. Brent Muhlestein, Catalin Toma, Craig Strauss, William Weintraub, Sandra Weiss, Anthony DeFranco, Stuart Pocock, Mark Effron, Stuart Keller, Brian Baker, Annapoorna Kini, Roxana Mehran, Timothy Henry
Journal: Journal of the American College of Cardiology (2016)
ANÁLISIS COMPARATIVO ENTRE PRÓTESIS DE APOSICIÓN LUMINAL CON Y SIN PIGTAIL EN EL DRENAJE TRANSMURAL GUIADO POR USE DE COLECCIONES PANCREÁTICAS
Authors: CF Consiglieri, J Busquets, N Peláez, L Secanella, M De La Hera, E García, J Fabregat, J Castellote, JB Gornals
Journal: Endoscopy (2016)

Introducción: La eficacia de las prótesis de aposición luminal (PAL) en el drenaje transmural guiado por USE (DT-USE) de colecciones pancreáticas (CP) es conocido, pero se han descrito obstrucciones completas y parciales de su luz intra-stent. La colocación de una prótesis plástica doble pigtail (PDP) coaxial puede ser beneficioso evitando el taponamiento y prevención de otros eventos adversos e incidencias.
Systemic Therapy for Previously Untreated Advanced <i>BRAF</i>-Mutated Melanoma
Authors: Tahira Devji, Oren Levine, Binod Neupane, Joseph Beyene, Feng Xie
Journal: JAMA Oncology (2016)

Multiple effective first-line systemic treatment options are available for patients with advanced BRAF-mutated melanoma. A lack of head-to-head randomized clinical trials (RCTs) comparing targeted and immunotherapies leaves uncertainty regarding optimal first-line treatment.To estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-mutated melanoma.We searched MEDLINE, Embase, and the Cochrane Central Registry of Controlled Trials for phase 2 or 3 RCTs published up until April 29, 2016.We included RCTs in which at least 1 intervention was a targeted (BRAF or MEK) or an immune checkpoint (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] or programmed cell death 1 [PD-1]) inhibitor.Two reviewers performed study selection, data abstraction, and risk of bias assessment. We performed a Bayesian network meta-analysis using a fixed-effect model to combine direct comparisons with indirect evidence. We estimated hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (OR) for objective response rate (ORR) and serious adverse events.Sixteen eligible articles reporting 15 RCTs involving 6662 patients assigned to 1 of 10 treatment strategies were included. Both BRAF/MEK and PD-1 were associated with improved OS benefit compared with all other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor. There was no significant difference in OS between BRAF/MEK and PD-1 (HR, 1.02; 95% credible interval [CrI], 0.72-1.45). The network meta-analysis showed a significant advantage of BRAF/MEK compared with all other treatment strategies for PFS. BRAF/MEK was associated with higher ORR (OR, 2.00; 95% CrI, 1.64-2.45) compared with BRAF alone, with both being superior in achieving ORR compared with other treatments. Chemotherapy and PD-1 were associated with lowest risk of serious adverse events. There was no significant difference in the risk of serious adverse events between chemotherapy and PD-1 (OR, 1.00; 95% CrI, 0.74-1.34).Compared with other treatments, BRAF/MEK and PD-1 inhibition significantly improved OS. The favorable safety profile of PD-1 inhibitors supports using this option as first-line therapy in circumstances where rapid response is not a priority.
TCT-225 Cliopidogril And Ticagrelor Highlights on Silent Holter Ambulatory Myocardial Ischemia (CATH SHAMI study)
Authors: Waleed Kadro, Jehad Muhanna, Maya Turkmani, Ruwaid Rumman, Malik Zawahrah, Hussam Alrahim
Journal: Journal of the American College of Cardiology (2016)
TCT-360 Impact of suture mediated femoral access site closure with the Prostar XL compared to the ProGlide system on outcome in transfemoral aortic valve implantation
Authors: Julia Seeger, Birgid Gonska, Christoph Rodewald, None Wolfgang Rottbauer, Jochen Wöhrle
Journal: Journal of the American College of Cardiology (2016)
A Pharmacokinetic Model of a Tissue Implantable Cortisol Sensor
Authors: Michael A. Lee, Naveed Bakh, Gili Bisker, Emery N. Brown, Michael S. Strano
Journal: Advanced Healthcare Materials (2016)

Cortisol is an important glucocorticoid hormone whose biochemistry influences numerous physiological and pathological processes. Moreover, it is a biomarker of interest for a number of conditions, including posttraumatic stress disorder, Cushing's syndrome, Addison's disease, and others. An implantable biosensor capable of real time monitoring of cortisol concentrations in adipose tissue may revolutionize the diagnosis and treatment of these disorders, as well as provide an invaluable research tool. Toward this end, a mathematical model, informed by the physiological literature, is developed to predict dynamic cortisol concentrations in adipose, muscle, and brain tissues, where a significant number of important processes with cortisol occur. The pharmacokinetic model is applied to both a prototypical, healthy male patient and a previously studied Cushing's disease patient. The model can also be used to inform the design of an implantable sensor by optimizing the sensor dissociation constant, apparent delay time, and magnitude of the sensor output versus system dynamics. Measurements from such a sensor would help to determine systemic cortisol levels, providing much needed insight for proper medical treatment for various cortisol‐related conditions.
TCT-570 Histology-Validated Neural Networks Enable Plaque Tissue and Thin-Capped Fibroatheroma Characterization Through Intravascular Optical Coherence Tomography Based Virtual Histology
Authors: Vikram Baruah, Aydin Zahedivash, Hoyt Taylor, Austin McElroy, Deborah Vela, L. Maximilian Buja, Thomas Milner, Marc Feldman
Journal: Journal of the American College of Cardiology (2016)
Alternating Combination Chemotherapy and Levamisole Improves Survival in Multiple Myeloma
Authors: Sydney E. Salmon, Arthur Haut, John D. Bonnet, Mammo Amare, James K. Weick, Brian G. M. Durie, Dennis O. Dixon
Journal: Journal of Clinical Oncology (1983)

In the August issue of the Journal, the article by Salmon et al (1:453–461, 1983) contained an error. At the request of the authors, the title of the article should not have included mention of Levamisole, but rather should have read "Alternating Combination Chemotherapy Improves Survival in Multiple Myeloma: A Southwest Oncology Group Study,"
TCT-433 Feasibility, self-correcting properties and one-month results after implantation of a novolimus eluting bioresorbable stent in coronary bifurcations. The BIFSORB pilot study
Authors: Emil Holck, Camilla Fox Maule, Trine Ørhøj Barkholt, Carlos Gutierrez Gutierrez, Shengxian Tu, Michael Maeng, Jouke Dijkstra, Evald Christiansen, Niels Holm
Journal: Journal of the American College of Cardiology (2016)
TCT-702 Transcatheter Aortic Valve Replacement: Predictors of 30-day readmission and in-hospital mortality during primary and readmission
Authors: Sidakpal Panaich, Shilpkumar Arora, Nilay Patel, Smit Patel, Harshil Shah, Chirag Savani, Kriti Narwal, Kosha Thakore, Aditi Amin, Sopan Lahewala, Nileshkumar Patel, Ekta Aneja, Abhishek Deshmukh, Apurva Badheka
Journal: Journal of the American College of Cardiology (2016)
TCT-830 Difference in Hemodynamic Micro-Environment in Vessels Scaffolded With ABSORB BVS or MIRAGE Microfiber Sirolimus Eluting Scaffold: A Pre-Clinical Study of Endothelial Shear Stress
Authors: Erhan Tenekecioglu, Ryo Torii, Christos Bourantas, Rafael Cavalcante, Yohei Sotomi, Yaping Zeng, Tom Crake, Alexandre Abizaid, Yoshinobu Onuma, Teguh Santoso, Patrick Serruys
Journal: Journal of the American College of Cardiology (2016)
A non-endoscopic device to sample the oesophageal microbiota: a case-control study
Authors: Daffolyn R Fels Elliott, Alan W Walker, Maria O'Donovan, Julian Parkhill, Rebecca C Fitzgerald
Journal: The Lancet. Gastroenterology & hepatology (2016)

The strongest risk factor for oesophageal adenocarcinoma is reflux disease, and the rising incidence of this coincides with the eradication of Helicobacter pylori, both of which might alter the oesophageal microbiota. We aimed to profile the microbiota at different stages of Barrett's carcinogenesis and investigate the Cytosponge as a minimally invasive tool for sampling the oesophageal microbiota.
IL-17 Receptor Signaling in the Lung Epithelium Is Required for Mucosal Chemokine Gradients and Pulmonary Host Defense against K. pneumoniae
Authors: Kong Chen, Taylor Eddens, Giraldina Trevejo-Nunez, Emily E. Way, Waleed Elsegeiny, David M. Ricks, Abhishek V. Garg, Carla J. Erb, Meihua Bo, Ting Wang, Wei Chen, Janet S. Lee, Sarah L. Gaffen, Jay K. Kolls
Journal: Cell Host & Microbe (2016)
Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease
Authors: Nadine Mykicki, Alexander M. Herrmann, Nicholas Schwab, René Deenen, Tim Sparwasser, Andreas Limmer, Lydia Wachsmuth, Luisa Klotz, Karl Köhrer, Cornelius Faber, Heinz Wiendl, Thomas A. Luger, Sven G. Meuth, Karin Loser
Journal: Science Translational Medicine (2016)

The approved drug NDP-MSH ameliorates neurodegeneration in mouse models of neuroinflammatory disease.
A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers
Authors: T. N. Shenkier, M. Hayes, K. A. Gelmon, S. Chia, C. Bajdik, B. Norris, S. Caroline, P. Hassell, S. E. O’Reilly, S. Allan, R. Yerushalmi
Journal: Journal of Clinical Oncology (2009)

e11510 Background: To determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC). To search for correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. Patients and Methods: Patients with LABC received eight cycles of either sequence A or B. Sequence A was doxorubicin 60 mg/m 2 and paclitaxel 175 mg/m 2 (AT) q3w X 4 followed by cisplatin (C) 60 mg/m 2 and paclitaxel 90 mg/m 2 (CT) q2w X 4. Sequence B was CT x 4 followed by AT x 4. In addition to estrogen receptor and HER2, immunohistochemistry (IHC) for MDR-1, MRP-1, topoisomerase IIα(topoIIα) and p53 was performed. Results: 88 patients were evaluable for response and toxicity. Median follow-up was 97 months. The overall pCR rate was 21.5%. For subgroups ER+/HER2-, HER2 +, and double negative (ER-/ HER2-) disease the pCR was 5.9%,23.3% and 35% respectively, p=0.006. Five year(y) overall survival for the entire cohort was 71.1%. Five y overall survival was 88.1% (CI 77.1%, 99.1%) for the ER positive HER2 negative group compared to 68.5% (CI 51.3%, 85.7%) and 49.5 (CI 27.4%, 71.6%) in the HER2 positive and “double negative” group respectively (p=0.0077). Over-expression of topo IIα was correlated with pCR (p&lt;0.001). There were no toxic deaths. Conclusions: A platinum-containing neoadjuvant regimen was well tolerated and achieved a pCR rate which compares favorably to other recent studies of multi-agent chemotherapy. Further studies tailored for specific breast cancer subtypes are required. No significant financial relationships to disclose.